[Skip to Content]
[Skip to Content Landing]

Conference Presentation: Effect of Selepressin vs Placebo on Ventilator- and Vasopressor-Free Days in Patients With Septic Shock: A Randomized Clinical Trial

In a 2019 randomized trial, selepressin--a selective vasopressin V1a receptor agonist hypothesized to mitigate sepsis-induced vasodilatation, vascular leakage, and tissue edema because of its absence of V1b- or V2-mediated effects--did not improve vasopressor- and ventilator-free days at 30 days among patients with septic shock. Pierre-François Laterre, MD, of St. Luc University Hospital, Université Catholique de Louvain in Brussels, Belgium, presents findings from the SEPSIS-ACT trial at the European Society of Intensive Care Medicine (ESICM) 32nd Annual Congress, LIVES 2019, on October 2 in Berlin. Click the related article link for full trial details. Video used with permission.

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close